Anthony B. El-Khoueiry

21.9k total citations · 4 hit papers
308 papers, 6.5k citations indexed

About

Anthony B. El-Khoueiry is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anthony B. El-Khoueiry has authored 308 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 220 papers in Oncology, 87 papers in Hepatology and 86 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anthony B. El-Khoueiry's work include Hepatocellular Carcinoma Treatment and Prognosis (85 papers), Cancer Immunotherapy and Biomarkers (75 papers) and Colorectal Cancer Treatments and Studies (68 papers). Anthony B. El-Khoueiry is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (85 papers), Cancer Immunotherapy and Biomarkers (75 papers) and Colorectal Cancer Treatments and Studies (68 papers). Anthony B. El-Khoueiry collaborates with scholars based in United States, Spain and United Kingdom. Anthony B. El-Khoueiry's co-authors include Heinz‐Josef Lenz, Bruno Sangro, Dongyun Yang, Robin Kate Kelley, Tim Meyer, Ignacio Melero, Jaclyn Neely, Ghassan K. Abou‐Alfa, Syma Iqbal and Charles D. Blanke and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Anthony B. El-Khoueiry

290 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline

2019 285 citations Anthony B. El-Khoueiry et al. Journal of Clinical Oncology profile →
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

2020 274 citations Ghassan K. Abou‐Alfa, Ann‐Lii Cheng et al. profile →
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

2022 269 citations Robin Kate Kelley, Anthony B. El-Khoueiry et al. profile →
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

2021 141 citations Anthony B. El-Khoueiry et al. profile →

Peers

Countries citing papers authored by Anthony B. El-Khoueiry

Since Specialization

Citations

This map shows the geographic impact of Anthony B. El-Khoueiry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony B. El-Khoueiry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony B. El-Khoueiry more than expected).

Fields of papers citing papers by Anthony B. El-Khoueiry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony B. El-Khoueiry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony B. El-Khoueiry. The network helps show where Anthony B. El-Khoueiry may publish in the future.

Co-authorship network of co-authors of Anthony B. El-Khoueiry

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony B. El-Khoueiry. A scholar is included among the top collaborators of Anthony B. El-Khoueiry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony B. El-Khoueiry. Anthony B. El-Khoueiry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma 2024 ·Oncotarget ·(unknown), Barbara J. Gitlitz, (unknown), Vinay Duddalwar, Kevin G. King, Anthony B. El-Khoueiry, Jacob Thomas, Denice Tsao‐Wei, David I. Quinn, Parkash S. Gill, Jorge J. Nieva	0
2	1006P Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors 2024 ·Annals of Oncology ·M. De Miguel, (unknown), Víctor Moreno, (unknown), Jessica Menis, Giuseppe Daniele, Anthony B. El-Khoueiry, Alexander I. Spira, Alessia Gravina, Anthony J. Olszanski, (unknown), (unknown), (unknown), (unknown), (unknown), William D. Hedrich, (unknown), Jinping Gan, Xiaorong Shi, Robert H.I. Andtbacka	0
3	Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC). 2024 ·Journal of Clinical Oncology ·Hye Ryun Kim, Omar Saavedra, Andrés Cervantes, Iwona Ługowska, (unknown), Anthony B. El-Khoueiry, Jacob Thomas, Wojciech Rogowski, Juanita Lopez, Byoung Yong Shim, Eric S. Christenson, Valentina Boni, Marina Chiara Garassino, Ramón Yarza, (unknown), (unknown), (unknown), (unknown), Michael Emig, (unknown)	9
4	Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma. 2024 ·Journal of Clinical Oncology ·Susanna V. Ulahannan, Thomas U. Marron, Haeseong Park, John M. Kaczmar, Ryan D. Stephenson, Nehal J. Lakhani, Greg Andrew Durm, Jaspreet Singh Grewal, Anthony B. El-Khoueiry, Jason J. Luke, Courtney Beers, Swaminathan Murugappan, Patricia LoRusso, Douglas R. Adkins, J. Randolph Hecht	2
5	Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Gerald S. Falchook, Patricia LoRusso, Jonathan W. Goldman, Anthony B. El-Khoueiry, Anthony W. Tolcher, Yan Xing, Jason T. Henry, Bhumsuk Keam, Dong‐Wan Kim, Tae-Yong Kim, (unknown), Min Hee Hong, Min Hwan Kim, (unknown), Sang Mi Lee, (unknown), John W. Hayslip, Cong Xu, Edward B. Garon	4
6	A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry, Elena Garralda, Andrés Cervantes, Candace L. Haddox, Hani M. Babiker, Mitesh J. Borad, Konstantinos Leventakos, Ranee Mehra, Jon Zugazagoitia, Diana L. Hanna, Guzmán Alonso, Angela Liu, Xiaorong Shi, (unknown), (unknown), William D. Hedrich, (unknown), (unknown), (unknown), Robert H.I. Andtbacka	1
7	A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009). 2024 ·Journal of Clinical Oncology ·Hao Xie, Anthony B. El-Khoueiry, Angela Alistar, Hani M. Babiker, Devalingam Mahalingam, Minal Barve, Joohyuk Sohn, Mitesh J. Borad, Jae-Cheol Lee, (unknown), (unknown), Jin‐Ho Choi, Jeongjun Kim, Donghoon Yu, Seungjoo Lee, (unknown), Stefan Proniuk, Jaeseung Kim, Kiyean Nam	2
8	International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI). 2024 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry, Tae‐You Kim, Jean‐Frédéric Blanc, Olivier Rosmorduc, Thomas Decaens, Philippe Mathurin, Philippe Merle, Farshid Dayyani, Gianluca Masi, Tiziana Pressiani, Peter R. Galle, Ken Hatogai, Yuko Ishii, Henrik Seidel, U. Mueller, Stacey Kalambakas, Mohamed Bouattour	13
9	821TiP Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis) 2023 ·Annals of Oncology ·Geoffrey I. Shapiro, Bristi Basu, Anthony B. El-Khoueiry, Sophie Postel‐Vinay, S-A. Im, Sun Young Rha, Claire F. Friedman, Antoîne Italiano, Young Mo Kim, (unknown), René L. Roux, (unknown), Michelle Brown, B. Webb, Natalia Lukashchuk, Emma Dean, (unknown), (unknown), Matthew Krebs	2
10	First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors 2022 ·Journal for ImmunoTherapy of Cancer ·Omid Hamid, Alberto Chiappori, John A. Thompson, Toshihiko Doi, Siwen Hu‐Lieskovan, Ferry A.L.M. Eskens, Willeke Ros, Adi Diab, Jean‐Philippe Spano, Naiyer A. Rizvi, Jeffrey S. Wasser, Eric Angevin, Patrick A. Ott, Alison Forgie, Wenjing Yang, Cen Guo, Jeffrey Chou, Anthony B. El-Khoueiry	37
11	Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies 2021 ·Clinical Cancer Research ·Melissa L. Johnson, Anthony B. El-Khoueiry, Navid Hafez, Nehal J. Lakhani, Hirva Mamdani, Jordi Rodón, Rachel E. Sanborn, (unknown), Valentina Boni, Mark Stroh, Alison L. Hannah, Song Wang, Henry Castro, Alexander I. Spira	45
12	Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma 2021 ·Liver Cancer ·Lorenza Rimassa, Robin Kate Kelley, Tim Meyer, Baek‐Yeol Ryoo, Philippe Merle, Joong‐Won Park, Jean‐Frédéric Blanc, Ho Yeong Lim, Albert Tran, Yi‐Wah Chan, Paul R. McAdam, Evelyn N. Wang, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou‐Alfa	22
13	A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors 2021 ·Cancer Chemotherapy and Pharmacology ·Jacob Thomas, Anthony B. El-Khoueiry, Barry J. Maurer, Susan Groshen, Jacek Pinski, Everardo Cobos, David R. Gandara, Heinz Josef Lenz, Min H. Kang, C. Patrick Reynolds, Edward M. Newman	14
14	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer 2020 ·Clinical Cancer Research ·Lipika Goyal, Cynthia A. Sirard, Michael Schrag, Michael H. Kagey, Jennifer R. Eads, Stacey Stein, Anthony B. El-Khoueiry, Gulam A. Manji, Thomas A. Abrams, Alok A. Khorana, Rebecca A. Miksad, Devalingam Mahalingam, Andrew X. Zhu, Dan G. Duda	46
15	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma 2020 ·Clinical Cancer Research ·Robin Kate Kelley, Tim Meyer, Lorenza Rimassa, Philippe Merle, Joong‐Won Park, Thomas Yau, Stephen L. Chan, Jean‐Frédéric Blanc, Vincent C. Tam, Albert Tran, Vincenzo Dadduzio, David W. Markby, Rajesh Kaldate, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou‐Alfa	66
16	A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer 2015 ·Clinical Cancer Research ·Alex A. Adjei, Donald Richards, Anthony B. El-Khoueiry, Fadi Braiteh, (unknown), Joe Stephenson, Aram F. Hezel, Morris Sherman, Lawrence Garbo, (unknown), Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li‐Tain Yeh, (unknown), David M. Wilson, Kimberly J. Manhard, Prabhu Rajagopalan, Heiko Krissel, Neil J. Clendeninn	16
17	A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Andrew J. Wagner, Wells A. Messersmith, M. Naveed Shaik, Sherry Li, Xianxian Zheng, Karen R. McLachlan, Rossano Cesari, Rachel Courtney, Wendy J. Levin, Anthony B. El-Khoueiry	61
18	Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer 2011 ·Clinical Cancer Research ·Armin Gerger, Anthony B. El-Khoueiry, Wu Zhang, Dongyun Yang, Harpreet Singh, Pierre Bohanes, Yan Ning, Thomas Winder, Melissa J. LaBonte, Peter M. Wilson, Léonor Benhaïm, David Páez, Rita El‐Khoueiry, Gudrun Absenger, Heinz‐Josef Lenz	72
19	The Dual EGFR/HER2 Inhibitor Lapatinib Synergistically Enhances the Antitumor Activity of the Histone Deacetylase Inhibitor Panobinostat in Colorectal Cancer Models 2011 ·Cancer Research ·Melissa J. LaBonte, Peter M. Wilson, (unknown), (unknown), Stan G. Louie, Anthony B. El-Khoueiry, Heinz‐Josef Lenz, Robert D. Ladner	79
20	Association of Methylenetetrahydrofolate Reductase Gene Polymorphisms and Sex-Specific Survival in Patients With Metastatic Colon Cancer 2007 ·Journal of Clinical Oncology ·Wu Zhang, Oliver W. Press, Christopher A. Haiman, Dongyun Yang, Michael A. Gordon, William Fazzone, Anthony B. El-Khoueiry, Syma Iqbal, Andy Sherrod, Georg Lurje, Heinz‐Josef Lenz	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact